Search

Displaying results 2741 - 2750 of 9670 in total
  1. Drug

    Tosedostat

    go.drugbank.com/drugs/DB11781
    Investigational

    It has demonstrated anti-tumour activity in a number of models of cancer, both as a single agent and in synergy with cytotoxic agents such as carboplatin and paclitaxel. … It entered the clinical trial in patients with haematological malignancies.

  2. Drug

    Diphenylguanidine

    go.drugbank.com/drugs/DB14191
    Approved

    Diphenylguanidine is a complexing agent used in the detection of metals and organic bases and used as an accelerator in the vulcanization of rubber. It is found in some rubber products. … It is also a dermatological sensitizer and allergen. Sensitivity to diphenylguanidine may be identified with a clinical patch test.

  3. Drug

    Crotalus scutulatus antivenin

    go.drugbank.com/drugs/DB13891
    Approved

    Since it was approved by the Food and Drug Administration in October 2000, crotalidae poyvalent immune Fab (CroFab) has largely replaced previously used crotaline antivenom. … It is intravenously administered to limit systemic toxicity [FDA label], [L2857], [L2858].

  4. Drug

    EVT 302

    go.drugbank.com/drugs/DB06057
    Investigational

    EVT 302 is an orally active, potent, highly selective and reversible inhibitor of MAO-B. It is in the development for smoking cessation, and potential for disease modification in Alzheimer's disease.

  5. Drug

    Palovarotene

    go.drugbank.com/drugs/DB05467
    Approved

    It first garnered interest as a potential treatment for emphysema but was eventually recognized as a potential novel therapy for patients with FOP. … [L39990,L40020] It has been granted rare pediatric disease and breakthrough therapy designations from the US FDA, although a previously submitted NDA was withdrawn in August 2021 pending the resubmission

  6. Drug

    Prezatide

    go.drugbank.com/drugs/DB11296
    Approved

    It is known to aid wound healing and its potential applications in chronic obstructive pulmonary disease and metastatic colon cancer are currently being investigated.

  7. Drug

    Sulisobenzone

    go.drugbank.com/drugs/DB11185
    Approved

    It works to filter out both UVA and UVB rays, protecting the skin from sun UV damage [L2153]. … Sulisobenzone is approved by the FDA in concentrations of up to 10% and in Canada, is approved by Health Canada at the same concentrations [F38].

  8. Drug

    Perhexiline

    go.drugbank.com/drugs/DB01074
    Approved

    It may cause neuropathy and hepatitis.

  9. Drug

    Defactinib

    go.drugbank.com/drugs/DB12282
    ApprovedInvestigational

    [L53198,L53208] FAK is important for the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, and its upregulation is a key … [L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian

  10. Drug

    Phenoxypropazine

    go.drugbank.com/drugs/DB09251
    ApprovedWithdrawn

    It was marketed as an antidepressant in 1961 but was later withdrawn in 1966 because of its hepatotoxic potential.